Synergy Pharmaceuticals Inc (NASDAQ:SGYP) completed the enrolment process for its phase IIb clinical study on its lead pipeline candidate, plecanatide. Plecanatide is being developed for the treatment of patients suffering from irritable bowel syndrome with constipation (IBS-C). Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stock opened at $5.20 in last trading session, and closed at $5.32 traded in the range of $5.17 – $5.44. The stock showed a positive weekly performance of 25.77%.
Synthetic Biologics Inc (NYSEMKT:SYN), announced the exercise of the over-allotment option granted to the underwriters to purchase an additional 1,725,000 shares of its common stock, at a price to the public of $1.00 per share, in connection with the Company’s recently announced underwritten public offering of 11,500,000 shares of common stock, bringing total gross proceeds from the offering to $13,225,000, before underwriting discounts and commissions and other offering expenses payable by the Company. Synthetic Biologics Inc (NYSEMKT:SYN) shares closed at $1.55 on last trade day, by decreasing -0.64%. Stock 52 week range is $0.95 – $2.10. Company’s market capitalization is $69.21 billion.
Directors and executives at Merrimack Pharmaceuticals Inc (NASDAQ:MACK) have snapped up more than $2 million worth of stock since shares hit an all-time low in November. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock fell 0.58% and finished the last session at $5.16. The EPS of the stock remained -1.26. Company’s market capitalization is $528.11 billion.
StemCells Inc (NASDAQ:STEM) has filed to sell $100 million worth of stock, warrants and debt securities and will use the money for general corporate purposes, including acquisitions.StemCells Inc (NASDAQ:STEM) stock opened at $1.30 in last trading session and closed at $1.28. The 52 week range of the stock is $1.16 – $2.13 and the day range was $1.23 – $1.33.